This approach targets the G12C mutation that represents around 12% of KRAS mutations in cancers (Cosmic database v86, https://cosmic-blog.sanger.ac.uk/), and is only present in a subset of cancers, such as non-small cell lung cancers22. This evidence concerns the gene KRAS and cancer.